Person:
OTÇU TEMUR, HAFİZE

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HAFİZE
Last Name
OTÇU TEMUR
Name
Email Address
Birth Date

Filters

2016 - 201912020 - 20211
Reset filters

Settings

Type: Article × Has files: false × Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Effectiveness of Using Dual-source CT and the Upshot it creates on Both Heart Rate and Image Quality
    (2016-05-01T00:00:00Z) Selcuk, Tuba; Otcu, Hafize; Yuceler, Zeyneb; Bilgili, Cigdem; Bulakci, Mesut; Savas, Yildiray; Celik, Omer; OTÇU TEMUR, HAFİZE
    Background: Early detection of coronary artery disease (CAD) is important because of the high morbidity and mortality rates. As invasive coronary angiography (ICA) is an invasive procedure, an alternative diagnostic method; coronary computed tomography angiography (CTA), has become more widely used by the improvements in detector technology.
  • No Thumbnail Available
    PublicationMetadata only
    Acute Myocarditis and Eculizumab Caused Severe Cholestasis in a 17-Month-Old Child Who Has Hemolytic Uremic Syndrome Associated with Shiga Toxin-Producing Escherichia coli
    (2021-09-01T00:00:00Z) YEŞİLBAŞ, Osman; Yozgat, Can Yilmaz; AKINCI, NURVER; SÖNMEZ, ŞİRİN; TEKİN, ESER; TALEBAZADEH, FARAZ; JAFAROV, UZEYİR; OTÇU TEMUR, Hafize; YOZGAT, YILMAZ; YEŞİLBAŞ, OSMAN; AKINCI, NURVER; SÖNMEZ, ŞİRİN; TEKİN, ESER; TALEBAZADEH, FARAZ; JAFAROV, UZEYİR; OTÇU TEMUR, HAFİZE; YOZGAT, YILMAZ
    Cardiovascular involvement is uncommon in pediatric patients with hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC-HUS). In this case report we presented a case of 17-month-old toddler who had a sporadic type of STEC-HUS complicated by acute myocarditis. The patient was successfully treated by a single dose of eculizumab after six doses of therapeutic plasma exchange (TPE) were inefficient to prevent the cardiac complication. Hepatotoxicity was observed after a single dose of eculizumab. Hepatic and cholestatic enzyme levels slowly returned to normal within 6 months. To the best of our knowledge, this is the first case of myocarditis/cardiomyopathy treated with eculizumab in STEC-HUS. This case illustrates the need for vigilance regarding myocardial involvement and eculizumab-induced hepatotoxicity in STEC-HUS.